New & Noteworthy

Mar 17, 2017
Pharmaceutical Executive
With big data one of the hot healthcare topics of the moment, we gauge pharma’s response to the hype to see if the industry is poised to take advantage of the promise of advanced analytics.
Mar 14, 2017
Pharmaceutical Executive
Amid the push for a more intelligent and predictive supply chain, is it imperative for pharma companies to advance with their supply chain digitization strategies now—or is there still time to “wait and see?”
Mar 09, 2017
Meg Alexander sounds a warning that providers of rare medicines may be the next to land in the hot seat.
Mar 06, 2017
Pharmaceutical Executive
Attack on treaties and imports threatens international operations.
Mar 06, 2017
The European Commission's latest economic assessment of EU member states does not make for comfortable reading, writes Reflector.
Mar 03, 2017
Pharm Exec speaks to Chris Molloy, CEO of the newly established Medicines Discovery Catapult, which aims to establish new approaches to grow and sustain the UK's reputation for innovative, fast-to-patient drug discovery.
Mar 02, 2017
Geoff Newman looks at how pharma and biotech interim management has evolved in the last 20 years.
Mar 01, 2017
Leela Barham looks at NICE's new position statement, which seeks to set out more clearly how it works with industry.
Feb 28, 2017
Pharmaceutical Executive
A panel of biopharma executives responsible for the Latin America business discuss investment, market access, and reimbursement issues in this key regional growth market for the life sciences industry.
Feb 21, 2017
Pharmaceutical Executive
Outlining one country’s unique price-setting model for novel drugs—and the resulting pre-launch strategies for manufacturers.
native1_300x100
lorem ipsum